Zenas BioPharma, Inc. (ZBIO) NASDAQ
17.40
+0.27(+1.58%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
17.40
+0.27(+1.58%)
Currency In USD
| Previous Close | 17.13 |
| Open | 17.16 |
| Day High | 17.78 |
| Day Low | 17.05 |
| 52-Week High | 44.6 |
| 52-Week Low | 8.91 |
| Volume | 410,351 |
| Average Volume | 683,429 |
| Market Cap | 776.79M |
| PE | -1.91 |
| EPS | -9.1 |
| Moving Average 50 Days | 19.8 |
| Moving Average 200 Days | 24.59 |
| Change | 0.27 |
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
GlobeNewswire Inc.
Feb 09, 2026 12:05 PM GMT
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week data support the robust and durable activity of obex
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 12:05 PM GMT
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformat
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
GlobeNewswire Inc.
Jan 05, 2026 12:05 PM GMT
- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically significant activity on all four key second